✦ Oct. 30: The FDA approved Biogen Inc. and Alkermes plc’s Vumerity (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. The agency approved the capsule through a new drug application under the 505(b)(2) pathway, with reference drug Tecfidera (dimethyl fumarate) from Biogen. The starting dose is 231 mg twice a day for seven days and then 462 mg, via two 231 mg capsules, twice a day. The companies priced the drug at $88,000 per year.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.